RobertStevenSiegelMD
Oncology • Washington, DCHematologic Oncology
Professor, Medicine, G Washington University School of Medicine & Hlth Sci
Overview of Dr. Siegel
Dr. Robert Siegel is an oncologist in Washington, DC and is affiliated with multiple hospitals in the area, including George Washington University Hospital and MedStar Georgetown University Hospital. He received his medical degree from George Washington University School of Medicine and has been in practice 40 years. Dr. Siegel accepts several types of health insurance, listed below. He is one of 96 doctors at MedStar Georgetown University Hospital and one of 38 doctors at George Washington University Hospital who specialize in Oncology. He has more than 40 publications and over 300 citings.
Office
2150 Pennsylvania Ave Nw
Washington, DC 20037Fax+1 202-741-3396
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 1980 - 1982- Duke University HospitalResidency, Internal Medicine, 1977 - 1980
George Washington University School of Medicine and Health SciencesClass of 1977
Certifications & Licensure
MD State Medical License 1992 - 2025
DC State Medical License 1982 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Super Doctor SuperDoctors.com
- Top MD Consumers Checkbook
Clinical Trials
- Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
- Induction Chemotherapy Followed by Surgery for Locally Advanced Head and Neck Cancer Start of enrollment: 2015 Jun 01
Publications & Presentations
PubMed
- 5 citationsPhase I Study of Entinostat in Combination with Enzalutamide for Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer.Jianqing Lin, Jacob Elkon, Brittany Ricart, Erica Palmer, Christian Zevallos-Delgado
The Oncologist. 2021-09-14 - 22 citationsNeoadjuvant chemotherapy and transoral surgery as a definitive treatment for oropharyngeal cancer: A feasible novel approach.Nader Sadeghi, Ning-Wei Li, M. Reza Taheri, Samantha Easley, Robert S. Siegel
Head & Neck. 2016-06-14 - 49 citationsThe significance of signet-ring cells in infiltrating lobular carcinoma of the breastAndra R. Frost, S Terahata, I T Yeh, R S Siegel, Beth Overmoyer
Archives of Pathology & Laboratory Medicine. 1995-01-01
Lectures
- Phase II study: Induction chemotherapy and transoral surgery as definitive treatment (Tx) for locally advanced oropharyngeal squamous cell carcinoma (OPSCC)—An updat...2019 ASCO Annual Meeting - 6/1/2019
- Phase II study: Induction chemotherapy and transoral surgery as definitive treatment (Tx) for locally advanced oropharyngeal squamous cell carcinoma (OPSCC): A novel a...2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
- Hematology and Medical Oncology Board Review CourseGeorge Washington University, Washington, Dist Of Col - 8/15/2013
Press Mentions
Dr. Siegel on Benefits with Transoral Surgery and Chemotherapy for Head and Neck CancerAugust 23rd, 2017- Dr. Siegel on Study of Induction Chemotherapy and Transoral Surgery in Oropharyngeal CancerAugust 22nd, 2017
- Novel Regimen May Eliminate Need for Radiation in Some Oropharyngeal CancersAugust 11th, 2017
Professional Memberships
- Member
Insurance Accepted
- Aetna Choice POS II
Anthem HealthKeepers HMO/POS
Anthem KeyCare PPO
BCBS Blue Card PPO
CareFirst BCBS Maryland POS
CareFirst BlueChoice Advantage
CareFirst BlueChoice Network POS
CareFirst BluePreferred PPO
CIGNA HMOCIGNA Open Access
CIGNA PPO
First Health PPO
Great West PPO
Multiplan PHCS PPO
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
